Similarly, patients with homozygous loss of CDKN2A/B loss had a median survival of 30.0 months (range: 2.3–167.6 months) compared to 71.6 months if their tumor harbored a heterozygous loss of CDKN2A/B (range: 5.8–164.8 months) or 136.8 months with no loss of CDKN2A/B (range: 0.1-262.2 months, P < .0001, Supplementary Material 10B). The gene discussed is CDKN2A; the disease is neoplasm.